No-moat Intellia Therapeutics' early-stage gene editing pipeline is continuing to make progress. We maintain our positive long-term outlook and fair value estimate of $85 per share. We view the stock as very undervalued, currently trading in 5-star territory. Intellia provides pure-play exposure to novel gene editing technology for long-term investors with a very high tolerance for risk. Pipeline candidate, NTLA-2002, is designed to inactivate a gene involved in potentially life-threatening inflammatory attacks for people suffering from hereditary angioedema. We like that Intellia is actively screening patients for its phase 3 study evaluating NTLA-2002, and we assign this pipeline candidate a 35% probability of approval in our base case. The clinical data looks positive, and we expect the phase 3 data could be released in 2026. Given time to review the data, submit regulatory filings, and prepare for a launch, we think it could reach the market in 2028, pending approvals.